Visit by Governor highlights major innovations in Cambridge
InferSens, a leading edge AI and machine learning sensor technology business backed by RO Capital Partners, is honoured to have welcomed Her Excellency the Honourable Dr Jeannette Young AC PSM, Governor of Queensland to its new headquarters at the St John’s Innovation Centre in Cambridge, UK.
In May 2022, RO Capital Partners announced that it had led a major seed investment round in InferSens alongside (amongst others) the Oxford Innovation Fund, and Bruce Melizan, the former MD of Interserve’s support services division to help accelerate the company’s product development and routes to market.
InferSens currently applies its expertise in tinyML – an emerging branch of machine learning that shrinks deep learning networks to fit on tiny, low powered hardware – to simplify and automate Legionella risk monitoring in properties.
The purpose of the Governor’s visit was to focus on innovative and leading start-ups in Cambridge.
Her Excellency the Honourable Dr Jeannette Young AC PSM, Governor of Queensland, said:
“We are delighted to have visited InferSens in Cambridge to discover their ground-breaking work in artificial intelligence and machine learning enabled water flow and temperature sensors.”
Colin Payne, CEO of InferSens, commented:
“We are extremely pleased to have welcomed the Governor of Queensland on an official visit to our new headquarters. It is a great honour for our company.
“InferSens’ first application is around using our technology to automate Legionella risk monitoring, supporting the maintenance of safe water systems, and preventing outbreaks such as Legionnaire’s disease, a global public health concern. The Governor is the former Chief Health Officer of Queensland, and we were therefore delighted to be given the opportunity to explain our application to her.”
Pictured from left to right:
Mr Raymond Siems
Mr Colin Payne, CEO InferSens
Her Excellency the Honourable Dr Jeanette Young PSM, Governor of Queensland
Professor Graeme Nimmo RDF, Spouse
Dr Jana Voigt, COO InferSens
Comments